BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Repromedix Corp. Launches Advanced Diagnostic Tests For Male Infertility


10/19/2005 5:11:07 PM

WOBURN, Mass., April 29 /PRNewswire/ -- Repromedix has launched a panel of two new advanced tests for male infertility that, taken together, provide the clearest indication of a sperm's ability to successfully achieve pregnancy and live birth. Taken together these tests go well beyond information provided by traditional sperm testing, such as count and motility.

Repromedix' Advanced Male Reproductive Potential Panel includes the Sperm DNA Fragmentation Assay (SDFA(TM)) and Sperm DNA Decondensation (SDD(TM)) Test. Results suggesting low to poor fertility potential indicate that a couple has little or no chance of conceiving a child naturally or through assisted reproductive technologies (ART) such as In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI). When conducted at the outset of infertility treatment, these tests could eliminate emotional and financial costs leading a couple to pursue other options, such as sperm donation or adoption.

Male infertility is a significant medical problem, with 40% of all infertility ascribed entirely or in part to male factors and an additional 20% unexplained. Data suggests that approximately 10-20% of the couples screened will have abnormal results from either the SDD test, the SDFA test, or both, and are unlikely to benefit from expensive, painful, and time consuming IVF procedures without treatment.

Launch of the highly complex male infertility tests comes just one month after Repromedix received $1.6 million in expansion investment capital from Brook Venture Partners LLC and the Massachusetts Business Development Corp in Wakefield, Mass.

Repromedix is the leading national laboratory specializing in advanced reproductive testing. By taking an interdisciplinary approach to clinical testing, the company helps doctors find solutions to their most difficult cases of female and male infertility, recurrent pregnancy loss, and high-risk pregnancy. The Woburn, Mass. based company was founded in 1994 by CEO Craig Sockol. It serves physicians and their patients throughout the United States and Canada.

Repromedix

CONTACT: Julie Dennehy for Repromedix, +1-508-533-8311


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->